ETOPOSIDE
Childhood Malignant Ovarian Germ Cell Tumor
Children's Oncology GroupSmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Childhood Malignant Ovarian Germ Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Children's Oncology Group | Phase 3 | BB |
BLEOMYCIN Children's Oncology Group | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Children's Oncology Group | Phase 3 | BB |
BLEOMYCIN Beihua Kong | Phase 3 | B |
FILGRASTIM Children's Oncology Group | Phase 2 | B |
Ifosfamide Children's Oncology Group | Phase 2 | B |
Eloxatin National Cancer Institute (NCI) | Phase 2 | B |
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →